Skip to main content

Advertisement

SpringerLink
Log in

Expression of IL-13Rα2 in liver cancer cells and its effect on targeted therapy of liver cancer

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Liver cancer is the third leading cause of cancer-related deaths globally. The number of liver cancers diagnosed in the world is increasing at an alarming rate. It is of great significance to find the new targets of the tumor cells and specific medicine. This research investigated the expression of interleukin-13 receptor α2 (IL-13Rα2) in different liver cancer cell lines and liver cancer tissues, and assessed the cytotoxin DT389-hIL13-13E13K (IL-13 and diphtheria toxin fusion protein) targeted killing effect on liver cancer cells. Based on study above, we further analyzed the function of IL-13Rα2 on the targeted liver cancer therapy. The results will provide a novel strategy and an alternative way for liver cancer therapy.

Methods

The expression of IL-13Rα2 in different liver cancer cell lines and tissues were analyzed by RT-PCR and immunohistochemistry. Cytotoxicity assay of DT389-hIL13-13E13K was performed in eight different concentrations in liver cancer cell lines in vitro. At the same time, siRNA-mediated knockdown was introduced to assess the role of IL-13Rα2 in liver cancer therapy.

Results

Two out of four tested liver cancer cell lines and 27 out of 33 (81.82%) liver tissues expressed the IL-13Rα2. The fusion protein DT389-hIL13-13E13K showed a moderate cytotoxicity to the cancer cell line BEL-7402 in vitro, which 50% inhibition (IC50) concentration occurred at 1.4 × 10−5 M. Besides, the sensitivity to fusion protein DT389-hIL13-13E13K was decreased in siRNA-transfected liver cells compared with control ones. These results suggest that IL-13Rα2 chain is a specific target for IL-13-directed fusion protein.

Conclusions

We reported the expression of IL-13Rα2 in liver cancer cell lines and tissues as well as investigated the cytotoxin (DT389-hIL13-13E13K) targeted killing efficiency of liver cancer cells and potential role of IL-13Rα2 in the cancer treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  • Donaldson DD, Whitters MJ, Fitz LJ, Neben TY, Finnerty H, Henderson SL, O’Hara RM Jr, Beier DR, Turner KJ, Wood CR, Collins M (1998) The murine IL-13 receptor a2: molecular cloning, characterization, and comparison with murine IL-13 receptor α1. J Immunol 161:2317–2324

    CAS  PubMed  Google Scholar 

  • Du J, Zheng YP, Sun W, Hu HG, Hou LL, Hong T (2008) Targeted killing effect of IL-13 diphtheria toxin fusion protein and DT389-hIL13-13E13K. J Med Res 37(10):31–36

    Google Scholar 

  • Fluckiger AC, Brière F, Zurawski G, Bridon JM, Banchereau J (1994) IL-13 has only a subset of IL-4-like activities on B chronic lymphocytic leukaemia cells. Immunology 83(3):397–403

    CAS  PubMed  Google Scholar 

  • Forner A, Hessheimer AJ, Isabel Real M, Bruix J (2006) Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol 60:89–98

    Article  PubMed  Google Scholar 

  • Greten TF, Papendorf F, Bleck JS, Kirchhoff T, Wohlberedt T, Kubicka S, Klempnauer J, Galanski M, Manns MP (2005) Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 92(10):1862–1868

    Article  CAS  PubMed  Google Scholar 

  • Husain SR, Puri RK (2000) Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi’s sarcoma xenograft. Blood 95(11):3506–3513

    CAS  PubMed  Google Scholar 

  • Jiang J, Nilsson-Ehle P, Xu N (2006) Influence of liver cancer on lipid and lipoprotein metabolism. Lipids Health Dis 5:4

    Article  PubMed  Google Scholar 

  • Joshi BH, Plautz GE, Puri RK (2000) Interleukin-13 Receptor α Chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 60(5):1168–1172

    CAS  PubMed  Google Scholar 

  • Kawakami K, Kawakami M, Sony PJ, Husain SR, Puri RK (2001) In vivo overexpression of IL-13 receptor α2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. J Exp Med 194(12):1743–1754

    Article  CAS  PubMed  Google Scholar 

  • Kawakami M, Kawakami K, Kasperbauer JL, Hinkley LL, Tsukuda M, Strome SE, Puri RK (2003) Interleukin-13 receptor α2 chain in human head and neck cancer serves as a unique diagnostic marker. Clin Cancer Res 9(17):6381–6388

    CAS  PubMed  Google Scholar 

  • Kawakami K, Kawakami M, Puri RK (2004a) Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease. Mol Cancer Ther 3(2):137–147

    CAS  PubMed  Google Scholar 

  • Kawakami M, Kawakami K, Takahashi S, Abe M, Puri RK (2004b) Analysis of interleukin-13 receptor α2 expression in human pediatric brain tumors. Cancer 101(5):1036–1042

    Article  CAS  PubMed  Google Scholar 

  • Kawakami K, Kioi M, Liu Q, Kawakami M, Puri RK (2005) Evidence that IL-13Rα2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy. J Immunother 28(3):193–202

    Article  CAS  PubMed  Google Scholar 

  • Kioi M, Kawakami K, Puri RK (2004) Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and pseudomonas exotoxin. Clin Cancer Res 10:6231–6238

    Article  CAS  PubMed  Google Scholar 

  • Kioi M, Kawakami M, Shimamura T, Husain SR, Puri RK (2006) Interleukin-13 receptor α2 China: a potential biomarker and molecular target for ovarian cancer therapy. Cancer 107(6):1407–1418

    Article  CAS  PubMed  Google Scholar 

  • Kioi M, Shimamura T, Nakashima H, Hirota M, Tohnai I, Husain SR, Puri RK (2009) IL-13 cytotoxin has potent antitumor activity and synergizes with paclitaxel in a mouse model of oral squamous cell carcinoma. Int J Cancer 124(6):1440–1448

    Article  CAS  PubMed  Google Scholar 

  • Kunwar S, Chang SM, Prados MD, Berger MS, Sampson JH, Croteau D, Sherman JW, Grahn AY, Shu VS, Dul JL, Husain SR, Joshi BH (2006) Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. Neurosurg Focus 20(4):E15

    PubMed  Google Scholar 

  • Li C, Hall WA, Jin N, Todhunter DA, Panoskaltsis-Mortari A, Vallera DA (2002) Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice. Protein Eng 15(5):419–427

    Article  PubMed  Google Scholar 

  • Parkin DM, Bray F, Ferlay J, Pisani P (2002) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108

    Article  Google Scholar 

  • Shimamura T, Fujisawa T, Husain SR, Kioi M, Nakajima A, Puri RK (2008) Novel role of IL-13 in fibrosis induced by nonalcoholic steatohepatitis and its amelioration by IL-13R-directed cytotoxin in a rat model. J Immunol 181:4656–4665

    CAS  PubMed  Google Scholar 

  • Vogelbaum MA, Sampson JH, Kunwar S, Chang SM, Shaffrey M, Asher AL, Lang FF, Croteau D, Parker K, Grahn AY, Sherman JW, Husain SR, Puri RK (2007) Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase I study of final safety results. Neurosurgery 61(5):1031–1038

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the Great Science and Technology Foundation of Beijing Jiaotong University (Grand No. 2004SZ010), and National Infrastructure of Natural Science and Technology Program (2005DKA21101), and Key Projects in the National Science and Technology Pillar Program during the Eleventh Five-Year Plan Period (2008BAK41B01-5). The authors thank Dr. Fuchou Tang for critical reading of the manuscript.

Author information

Authors and Affiliations

  1. College of Life Sciences and Bioengineering, Beijing Jiaotong University, 100044, Beijing, People’s Republic of China

    Lingling Hou, Juan Du, Yanfeng Liu, Weimin Sun, Yanpeng Zheng, Lishu Zhang, Honggang Hu, Xinxian Dai & Tao Hong

  2. Institute of Pathogen Biology, Peking Union Medical College, Chinese Academy of Medical Sciences, 100730, Beijing, People’s Republic of China

    Jianwei Wang

  3. Institute of Animal Sciences, Chinese Academy of Agricultural Sciences (CAAS), 100193, Beijing, People’s Republic of China

    Weijun Guan & Yuehui Ma

Authors
  1. Lingling Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juan Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jianwei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yanfeng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Weimin Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yanpeng Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lishu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Honggang Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Xinxian Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Weijun Guan
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yuehui Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Tao Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Lingling Hou, Weijun Guan or Yuehui Ma.

Additional information

Lingling Hou and Juan Du contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hou, L., Du, J., Wang, J. et al. Expression of IL-13Rα2 in liver cancer cells and its effect on targeted therapy of liver cancer. J Cancer Res Clin Oncol 136, 839–846 (2010). https://doi.org/10.1007/s00432-009-0724-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-009-0724-z

Keywords

Search

Navigation